S
Shots:
Omeros submitted an MAA to the EMA for narsoplimab to treat TA-TMA, with data demonstrating a 61% response rate and a 3x improvement in OS vs matched external controls; over 130 pts treated under expanded access data were also included
EMA granted Narsoplimab ODD status, and CHMP review will start mid-July under centralized…
